Minneapolis, Minn., June 20, 2016 – Pharmacogenomics company OneOme is pleased to announce key business milestones in advance of launching its RightMed test.
The RightMed test is a cost-effective, comprehensive, personalized pharmacogenomic analysis of 22 genes provided at the point of care. The test helps providers easily make personalized treatment decisions across more than 300 medications for more than 20 medical indications.
The OneOme platform was co-developed and exclusively licensed from Mayo Clinic to bring pharmacogenomics into routine clinical care. OneOme’s RightMed test is currently in use by Mayo Clinic Center for Individualized Medicine (CIM).
OneOme recently welcomed Aaron Solomon as Vice President of Global Sales. Aaron brings more than two decades of high-performance sales leadership experience, most recently leading business development and international commercialization at Invitae, a hereditary disease diagnostics company.
“We each have a unique genetic profile which affects how we respond to drugs. Pharmacogenomics is the sharp tip of the spear to enabling precision medicine,” said Solomon. “I am excited to be leading the commercial efforts to help drive the adoption of pharmacogenomics to improve patient care and reduce overall healthcare costs.”
OneOme will be exhibiting at the University of Minnesota Precision Medicine conference this week, where local and regional physicians, pharmacists, and other clinicians will be discussing the implementation of pharmacogenomic testing in the clinic.
OneOme’s RightMed pharmacogenomic test helps healthcare providers with timely, evidence-based prescription decisions by combining a patient’s genetic profile and current medications in an interactive report that easily integrates into current care. The RightMed test is ordered by providers for use in patient consultation and care. While anyone can take the test, it is most beneficial for patients with adverse drug reactions, cardiovascular drug prescriptions, medications that are not working, multiple prescription medications, and unwelcome side effects from current medications.
OneOme is a privately held company backed by early-stage venture firm Invenshure, LLC, and Mayo Clinic. To learn more about OneOme, visit www.oneome.com.